Clinical Trials for Other Solid Tumor

Dose-finding Phase 1 Trial: Evaluating Safety and Biomarkers Using DK210 (EGFR) for Inoperable Locally Advanced and/or Metastatic EGFR+ Tumors With Progressive Disease Failing Systemic Therapy

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial is designed for adult patients with EGFR-positive advanced solid tumors that have progressed after systemic therapy, focusing on assessing the safety and optimal dosing of the investigational drug DK210, an EGFR-targeting agent, administered alone or with standard therapies.

ClinicalTrials.gov ID: NCT05704985

A First-in-human Dose Escalation and Optimization Phase I/IIa Study to Investigate Safety, Tolerability, PK, and Efficacy of the NaPi2b ADC TUB-040 in Patients With Platinum-resistant High-grade Ovarian Cancer (PROC) or r/r Adenocarcinoma Non-small Cell Lung Cancer (NSCLC)

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial involves patients with platinum-resistant high-grade ovarian cancer or relapsed/refractory non-small cell lung cancer, assessing the safety and efficacy of TUB-040, an antibody-drug conjugate targeting NaPi2b with a topoisomerase I inhibitor, administered every three weeks.

ClinicalTrials.gov ID: NCT06303505

A Dose-Escalation and Expansion Study of XB010 as a Single Agent and Combination Therapy in Subjects With Locally Advanced or Metastatic Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: The trial evaluates the investigational antibody-drug conjugate XB010, which targets the 5T4 antigen to inhibit tumor growth, in adults with locally advanced or metastatic solid tumors who lack alternative treatment options; it assesses XB010 as both a monotherapy and in combination with pembrolizumab across various tumor types including non-small cell lung cancer, hormone-receptor-positive and triple-negative breast cancer, head and neck, and esophageal squamous cell cancers.

ClinicalTrials.gov ID: NCT06545331

A Phase 1/2, Open-Label, Multi-Center, Dose Escalation and Expansion Study Evaluating the Safety, Tolerability and Clinical Activity of DECOY20 as Monotherapy and in Combination With Tislelizumab in Patients With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, including specific types like hepatocellular carcinoma and non-small cell lung cancer, who have exhausted standard treatments, and assesses the safety and clinical activity of Decoy20, a Toll-like receptor agonist immunotherapy, both alone and in combination with the PD-1 inhibitor tislelizumab.

ClinicalTrials.gov ID: NCT05651022

A Phase 1, Open-label, Dose Escalation and Dose Expansion Study for LNCB74, a B7-H4 Targeted Antibody Drug Conjugate, as Monotherapy in Participants With Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates LNCB74, a B7-H4 targeted antibody-drug conjugate, as monotherapy for adults with advanced, unresectable, or metastatic solid tumors that express B7-H4, aiming to evaluate its safety, tolerability, and efficacy. Participants must have measurable disease, an ECOG performance status of 0-1, and adequate organ function.

ClinicalTrials.gov ID: NCT06774963

A Phase 1, Multicenter, Open-label, Dose-escalation Study Evaluating the Safety and Tolerability of Intravenous KK2269 Monotherapy and Combination Therapy With Docetaxel in Adult Participants With Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial involves adult patients with advanced solid tumors, focusing on gastric, GEJ, esophageal adenocarcinomas, and NSCLC, testing KK2269, a bispecific antibody targeting CD40 and EpCAM, alone and in combination with docetaxel to assess safety and tolerability.

ClinicalTrials.gov ID: NCT06266299

Phase I/II First-in-Human Study of TT-10 (PORT-6), an Adenosine 2A Receptor Antagonist, and PORT-7, an Adenosine 2B Receptor Antagonist, as Single Agents and in Combination in Participants With Advanced Selected Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls patients aged 18 and older with advanced solid tumors, including RCC, CRPC, NSCLC, SCCHN, CRC, endometrial, and ovarian cancers, who have failed or are ineligible for standard treatments, to evaluate TT-10, an adenosine A2A receptor antagonist, and TT-4, an adenosine A2B receptor antagonist, administered as single agents and in combination.

ClinicalTrials.gov ID: NCT04969315

A Phase 1/1b Open-label Study of BMS-986488 as Monotherapy and Combination Therapy in Participants With Advanced Malignant Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial investigates the safety and anti-tumor activity of the investigational drug BMS-986488, alone or combined with adagrasib, cetuximab, or nivolumab, in adults with advanced malignant tumors, including specific cohorts with ccRCC, NSCLC (KRAS G12C mutation), ccOC, and CRC (KRAS G12C mutation).

ClinicalTrials.gov ID: NCT06764771

A Phase 1/1b Study of IAM1363 in Patients with Advanced Cancers Harboring HER2 Alterations

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial evaluates IAM1363, an oral, irreversible tyrosine kinase inhibitor targeting HER2 mutations, in adult patients with advanced cancers harboring HER2 alterations who have relapsed or are intolerant to previous therapies, including a subgroup with brain metastases.

ClinicalTrials.gov ID: NCT06253871

A Seamless Phase 1/2 Study to Evaluate the Safety and Efficacy of A2B395, an Allogeneic Logic-gated Tmod™ CAR T, in Heterozygous HLA-A*02 Adults With Recurrent Unresectable, Locally Advanced, or Metastatic Solid Tumors That Express EGFR and Have Lost HLA-A*02 Expression

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

HealthScout AI summary: This trial enrolls adults with recurrent unresectable, locally advanced, or metastatic solid tumors that express EGFR and have lost HLA-A*02 expression, including types such as CRC, NSCLC, HNSCC, TNBC, and RCC, and tests A2B395, a logic-gated Tmod™ CAR T-cell therapy designed to selectively target these tumor cells while sparing healthy cells. Participants receive a preconditioning lymphodepletion regimen followed by a single intravenous dose of A2B395.

ClinicalTrials.gov ID: NCT06682793